Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of human carbonyl reductase 1 (CBR1) in livers from black and white donors.

Drug metabolism and disposition: the biological fate of chemicals - 1 Feb 2009

Gonzalez-Covarrubias Vanessa, Zhang Jianping, Kalabus James L, Relling Mary V, Blanco Javier G

Abstract excerpt

Carbonyl reductase 1 (CBR1) reduces the anticancer drug doxorubicin into the cardiotoxic metabolite doxorubicinol. We documented the hepatic expression of CBR1 in samples from white and black donors. Concordance between ethnicity and geographical ancestry was examined with ancestry informative markers. Livers from blacks and whites showed similar CBR1 mRNA levels (CBR1 mRNA(blacks) = 4.8 +/- 4.3 relative -fold...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotics, Antineoplastic
Share to Black People

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Doxorubicin

Share to Genotype

Share to Pharmacogenetics

Share to Polymorphism, Genetic

Share to Tissue Donors

Share to White People

Source

Open in PubMed Open full text

Identifiers

PMID: 19022938
DOI: 10.1124/dmd.108.024547
PMCID: PMC2680526

Genes

CBR1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of human carbonyl reductase 1 (CBR1) in livers from black and white donors.PMID 19022938Read ↗

A functional genetic polymorphism on human carbonyl reductase 1 (CBR1 V88I) impacts on catalytic activity and NADPH binding affinity.Semantic proximity Read ↗

Identification of the promoter of human carbonyl reductase 3 (CBR3) and impact of common promoter polymorphisms on hepatic CBR3 mRNA expression.Semantic proximity Read ↗

Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity.Semantic proximity Read ↗

CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients.Semantic proximity Read ↗

Expression of the anthracycline-metabolizing enzyme carbonyl reductase 1 in hearts from donors with Down syndrome.Semantic proximity Read ↗

Higher activity of polymorphic NAD(P)H:quinone oxidoreductase in liver cytosols from blacks compared to whites.Semantic proximity Read ↗

Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.Semantic proximity Read ↗

Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin.Semantic proximity Read ↗

Pharmacogenetics of genes across the doxorubicin pathway.Semantic proximity Read ↗

Risk factors for anthracycline-associated cardiotoxicity.Semantic proximity Read ↗

Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1.Semantic proximity Read ↗

Interindividual variability in the cardiac expression of anthracycline reductases in donors with and without Down syndrome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.